Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2013. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility regarding their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details rather than financial performance metrics.
Material Changes
The filing details the acquisition of Ordinary Shares by various directors and executives on April 11, 2013. These acquisitions resulted from the reinvestment of dividends paid on shares held in the GlaxoSmithKline ShareReward Plan. The purchase price was 1560.192 pence per Ordinary Share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of specific share transactions.
Important Facts for Investors
- Transaction Date: April 11, 2013.
- Share Price: 1560.192 pence per Ordinary Share.
- Transaction Type: Dividend reinvestment via the ShareReward Plan.
- Key Participants: Sir Andrew Witty (31 shares), Mr S M Bicknell (46 shares), Mr D S Redfern (46 shares), Ms C Thomas (46 shares), and other listed directors.
- Notification Date: April 12, 2013.